| Autor: |
Januka Khanal, Daniel P. Cahill, Joseph Buehler, Diana D. Shi, Yu-Fen Lin, Misty S. Martin-Sandoval, Michael M Levitt, Keith L. Ligon, Harley I. Kornblum, Adam C. Wang, Sungwoo Lee, Dennis M. Bonal, John M. Asara, Mark A. Lehrman, Isaac S. Harris, Andreas Janzer, Cylaina E. Bird, Michael Jeffers, Ralph J. DeBerardinis, William G. Kaelin, Tammie Dang, Nathalie Y. R. Agar, Sylwia A. Stopka, Lauren C. Gattie, Stefan Gradl, Lauren G. Zacharias, Michael S. Regan, Quang-Dé Nguyen, Tak W. Mak, Sabina Signoretti, Kalil G. Abdullah, Peter Ly, Andreas Sutter, Timothy E. Richardson, Samuel K. McBrayer, Thomas P. Mathews, Milan R. Savani, Jennifer E. Endress, Min Xu, Wenhua Gao, Bofu Huang, Rebecca B. Jennings, Ryan E. Looper |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.11.30.470443 |
| Popis: |
SUMMARYMutations affecting isocitrate dehydrogenase (IDH) enzymes are prevalent in glioma, leukemia, and other cancers. Although mutant IDH inhibitors are effective against leukemia, they appear less active in aggressive glioma, underscoring the need for alternative treatment strategies. Through a chemical synthetic lethality screen, we discovered that IDH1 mutant glioma cells are hypersensitive to drugs targeting enzymes in the de novo pyrimidine nucleotide synthesis pathway, including dihydroorotate dehydrogenase (DHODH). We developed a genetically engineered mouse model of mutant IDH1-driven astrocytoma and used it and multiple patient-derived models to show that the brain-penetrant DHODH inhibitor BAY 2402234 displays monotherapy efficacy against IDH mutant gliomas. Mechanistically, this vulnerability selectively applies to de novo pyrimidine, but not purine, synthesis because glioma cells engage disparate programs to produce these nucleotide species and because IDH oncogenes increase DNA damage upon nucleotide pool imbalance. Our work outlines a tumor-selective, biomarker-guided therapeutic strategy that is poised for clinical translation. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
